Skip to content

A clinical trial to find the efficacy and safety of â??Hypercumâ?? for the treatment of hypertension

An open labeled clinical trial to evaluate the efficacy and safety of â??Hypercumâ?? for the treatment of hypertension and associated complications

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/09/003020
Enrollment
16
Registered
2012-09-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I15- Secondary hypertension

Interventions

Intervention1: Hypercum: Hypercum contains â?¢ Rauvolfia Serpentina â?¢ Nardostachys Jatamanshi â?¢ Allium Sativam â?¢ Ocimum Sanctum â?¢ Curcumin Longa â?¢ Embilica Officinalis â?¢ Azadirachta Indic

Sponsors

MS Natural Solutions
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Males and females of age group 18-60 years • Subjects who are willing to give written informed consent • Patient running with Anti Hypertensive drugs or patient having known to be a Hypertensive patient but not yet approached any system of medication. • Diabetic Patient or Patient running with Renal Failure or Patient having Metabolic Syndrome • Female subjects who are confirmed as non-pregnant status and agree to comply with proper contraception throughout the study duration • Patient is willing and able to comply with all trial requirements

Exclusion criteria

Exclusion criteria: • Severe essential hypertension • Significant renal insufficiency [Serum Creatinine > 159 µmol/L ( > 1.8 mg/dl)] • History of cerebro-vascular disease • Patients with a history of HIV infection, AIDS, hepatitis B or C, or other immunosuppressive disorders • Current diagnosis or a history of malignancy • Drug of abuse within the past 2 years • Pregnancy or breastfeeding • Present history of mental diseases • Previous participation in a clinical trial within 6 months

Design outcomes

Primary

MeasureTime frame
â?¢ Reduction in DBP & SBP from base line â?¢ Change in mean arterial blood pressure â?¢ Reduction of hypertension related complications over 3 months Timepoint: All visits

Secondary

MeasureTime frame
â?¢ Quality of life SF-36 questionnaire â?¢ Adverse Events recording in all visits. â?¢ Laboratory tests (Haematology, Biochemistry and urine analysis) at base line and post study Timepoint: Pre and post study

Countries

India

Contacts

Public ContactVikram Baburao

Natural Solutions

dranil1965@gmail.com02226316777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026